Association of Midgestational Paraoxonase 1 Activity with Pregnancies Complicated by Preeclampsia

Arthur M Baker; Richard L Klein; Sina Haeri; Kevin L Moss; Kim A Boggess

doi:10.1055/s-0029-1236438

American Journal of Perinatology, Table of Contents

Am J Perinatol 2010; 27(3): 205-210
DOI: 10.1055/s-0029-1236438

Association of Midgestational Paraoxonase 1 Activity with Pregnancies Complicated by Preeclampsia

Arthur M. Baker¹ , Richard L. Klein² ^, ³ , Sina Haeri¹ , Kevin L. Moss⁴ , Kim A. Boggess¹

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina
²Division of Endocrinology, Metabolism, and Medical Genetics, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina
³Research Service, Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina
⁴Department of Dentistry, University of North Carolina, Chapel Hill, North Carolina

Abstract

ABSTRACT

The antioxidant enzyme paraoxonase 1 is a marker of oxidative stress and has been implicated in the pathogenesis of preeclampsia. Our objective was to determine if an association exists between low paraoxonase 1 activity at midgestation and the development of preeclampsia. We conducted a case-control study of 50 women with preeclampsia and 101 women with uncomplicated term deliveries. Maternal serum collected at 15 to 20 weeks was used to measure paraoxonase 1 activity using two substrates: paraoxon and phenylacetate (arylesterase activity). The groups did not differ with respect to maternal demographics. Paraoxonase 1 activity (paraoxon) was significantly higher in women with preeclampsia compared with controls (19.4 ± 9.4 versus 15.6 ± 8.0 change in absorbance per minute (dA/min), p = 0.009). When stratified by disease severity, paraoxonase 1 activity (paraoxon) was highest in women with severe preeclampsia (21.6 ± 9.1 versus 15.6 ± 8.0 dA/min, p = 0.002). We observed a trend toward higher arylesterase activity in women with preeclampsia compared with controls (0.343 ± 0.07 versus 0.323 ± 0.06 dA/min, p = 0.06). Midgestational paraoxonase 1 activity is higher in women with preeclampsia before clinical signs of the disease are present. Prospective studies are needed to determine the significance of paraoxonase 1 in the pathogenesis of preeclampsia.

KEYWORDS

Lipid dysfunction - oxidative stress - paraoxonase - preeclampsia

Full Text

References

REFERENCES

1 Saftlas A F, Olson D R, Franks A L, Atrash H K, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979–1986. Am J Obstet Gynecol. 1990; 163 460-465
2 Centers for Disease Control and Prevention (CDC) . Maternal mortality—United States, 1982–1996. MMWR Morb Mortal Wkly Rep. 1998; 47 705-707
3 Sibai B M, Gordon T, Thom E The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Am J Obstet Gynecol. 1995; 172(2 Pt 1) 642-648
4 Dekker G, Kraayenbrink A. Oxygen free radicals in preeclampsia. Am J Obstet Gynecol. 1991; 164 273-278
5 Uotila J T, Tuimala R J, Aarnio T M, Pyykkö K A, Ahotupa M O. Findings on lipid peroxidation and antioxidant function in hypertensive complications of pregnancy. Br J Obstet Gynaecol. 1993; 100 270-276
6 Akyol D, Mungan T, Görkemli H, Nuhoglu G. Maternal levels of vitamin E in normal and preeclamptic pregnancy. Arch Gynecol Obstet. 2000; 263 151-155
7 Sağol S, Ozkinay E, Ozşener S. Impaired antioxidant activity in women with pre-eclampsia. Int J Gynaecol Obstet. 1999; 64 121-127
8 Kharb S. Total free radical trapping antioxidant potential in pre-eclampsia. Int J Gynaecol Obstet. 2000; 69 23-26
9 Madazli R, Benian A, Aydin S, Uzun H, Tolun N. The plasma and placental levels of malondialdehyde, glutathione and superoxide dismutase in pre-eclampsia. J Obstet Gynaecol. 2002; 22 477-480
10 Knapen M F, Mulder T P, Van Rooij I A, Peters W H, Steegers E A. Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol. 1998; 92 1012-1015
11 Smith G C, Pell J P, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001; 357 2002-2006
12 Irgens H U, Reisaeter L, Irgens L M, Lie R T. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001; 323 1213-1217
13 Katabuchi H, Yih S, Ohba T et al.. Characterization of macrophages in the decidual atherotic spiral artery with special reference to the cytology of foam cells. Med Electron Microsc. 2003; 36 253-262
14 Costa L G, Vitalone A, Cole T B, Furlong C E. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005; 69 541-550
15 Deakin S, Leviev I, Guernier S, James R W. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003; 23 2083-2089
16 Durrington P N, Mackness B, Mackness M I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21 473-480
17 Mackness B, Durrington P, McElduff P et al.. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003; 107 2775-2779
18 Mackness M I, Harty D, Bhatnagar D et al.. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991; 86 193-199
19 Mackness B, Mackness M I, Arrol S et al.. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998; 139 341-349
20 Dantoine T F, Debord J, Charmes J P et al.. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998; 9 2082-2088
21 ACOG Committee on Practice Bulletins--Obstetrics . ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002; 99 159-167
22 Gan K N, Smolen A, Eckerson H W, La Du B N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991; 19 100-106
23 Kumru S, Aydin S, Gursu M F, Ozcan Z. Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women. Eur J Obstet Gynecol Reprod Biol. 2004; 114 177-181
24 Uzun H, Benian A, Madazli R, Topçuoğlu M A, Aydin S, Albayrak M. Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia. Gynecol Obstet Invest. 2005; 60 195-200
25 Sarandöl E, Safak O, Dirican M, Uncu G. Oxidizability of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in preeclampsia. Clin Biochem. 2004; 37 990-996

Arthur M BakerM.D.

Department of Obstetrics and Gynecology, University of North Carolina, 3010 Old Clinic Building

CB#7516, Chapel Hill, NC 27599-7516

Email: abaker2@med.unc.edu